Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Current Trends and Future Directions in the Treatment of Advanced...
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Current Trends and Future Directions in the Treatment of Advanced Urological Cancers

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: closed (25 August 2024) | Viewed by 1079

Special Issue Editor

Dr. Dimitrios Makrakis

E-Mail
Guest Editor
Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
Interests: genitourinary cancers; lung cancer; immunotherapy; clinical trials; checkpoint inhibitors; biomarkers

Special Issue Information

Dear Colleagues,

The Journal of Clinical Medicine announces a new Special Issue “Current Trends and Future Directions in the Treatment of Advanced Urological Cancers”.

Advanced urological malignancies comprise a diverse group of cancers including bladder, prostate and kidney cancer, each posing unique therapeutic challenges Bladder cancer remains an aggressive tumor with poor outcomes; recent advances for metastatic BC, such as the combination of Immune Checkpoint Inhibitors (ICIs) and Antibody Drug Conjugates, are changing the therapeutic landscape, but adverse events and patient selection remain an issue.

In metastatic renal cell carcinoma, ICIs significantly changed first line treatment; however, management after progression remains unclear, highlighting the need for new therapeutic strategies. Recent developments such as the characterization of Hypoxia-Induced Factor-1 are promising but more data are needed to inform trials and clinical decisions.

In prostate cancer, practice-changing advances in the treatment of localized, hormone sensitive tumors are not reflected in metastatic, castration-resistant disease (mCRPC); new therapeutic tools such as the PSMA-lutetium scan and ICIs have been introduced, alongside genetic features such as Mismatch Repair and Microsatellite Instability, bringing insight into different patient populations with diverse cancer subtypes.

The aim of this Special Issue is to provide new insights and data on the therapeutic management of advanced urological malignancies.

Dr. Dimitrios Makrakis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • checkpoint inhibitors
  • advanced bladder cancer
  • bladder cancer histological variants
  • metastatic RCC
  • castration-resistant prostate cancer
  • prostate cancer immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 931 KiB  
Article
Elderly Prostate Cancer Patients Treated with Robotic Surgery Are More Likely to Harbor Adverse Pathology Features and Experience Disease Progression: Analysis of the Prognostic Impact of Adverse Pathology Risk Score Patterns Using Briganti’s 2012 Nomogram and EAU Risk Groups
by Antonio Benito Porcaro, Emanuele Serafin, Francesca Montanaro, Sonia Costantino, Lorenzo De Bon, Alberto Baielli, Francesco Artoni, Luca Roggero, Claudio Brancelli, Michele Boldini, Alberto Bianchi, Alessandro Veccia, Riccardo Rizzetto, Matteo Brunelli, Maria Angela Cerruto, Riccardo Giuseppe Bertolo and Alessandro Antonelli
J. Clin. Med. 2025, 14(1), 193; https://doi.org/10.3390/jcm14010193 - 31 Dec 2024
Viewed by 725
Abstract
Background/Objectives: Prostate cancer (PCa) is prevalent among men over 70. Treatment may involve interventions like radical prostatectomy. The objective of this study was to investigate the combination of adverse pathology patterns on PCa progression through the Briganti 2012 nomogram and EAU risk classes [...] Read more.
Background/Objectives: Prostate cancer (PCa) is prevalent among men over 70. Treatment may involve interventions like radical prostatectomy. The objective of this study was to investigate the combination of adverse pathology patterns on PCa progression through the Briganti 2012 nomogram and EAU risk classes in elderly patients treated with robotic surgery. Methods: A cohort of 1047 patients treated from January 2013 to December 2021 was categorized as being older if aged 70 or above. The adverse pathology risk scores were ranked from zero to three. These scores were then analyzed for correlations with the Briganti 2012 nomogram via EAU risk groups and for PCa progression. Results: Overall, older age was detected in 287 patients who had higher rates of adverse pathology features combined into a pattern risk score of 3. Within each age group, the adverse pathology risk score patterns were positively predicted by the Briganti 2012 nomogram across EAU prognostic groups. After a median (95% CI) follow-up period of 95 months, PCa progression occurred in 237 patients, of whom 68 were elderly and more likely to progress as adverse pathology patterns increased, particularly for a risk score of 3 (p < 0.0001), which was almost three times higher than that in younger patients (p < 0.0001). Conclusions: Managing PCa in elderly patients is challenging due to their increasing life expectancy. The Briganti 2012 nomogram effectively predicts disease progression in this population. Elderly prostate cancer patients have higher severe pathology rates predicted independently by the Briganti 2012 nomogram, with nearly triple the risk of progression compared to that in younger cases, necessitating tailored treatment approaches. Full article
(This article belongs to the Special Issue Current Trends and Future Directions in the Treatment of Advanced Urological Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop